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Combination of a clinical risk assessment
score and rapid whole blood D-dimer
testing in the diagnosis of deep vein
thrombosis in symptomatic patients
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Serunkuma, BSc, Zak A. Zarka, MSc, MD, Styliani E. Daskalopoulou, MB,
BS, and Andrew N. Nicolaides, MS, FRCS, London, United Kingdom
Purpose: The clinical diagnosis of deep vein thrombosis (DVT) is unreliable in more than
50% of cases, and, in recent years, plasma D-dimer assays have been used to predict the
presence of DVT with high sensitivity and negative predictive values. This study inves-
tigated the use of a rapid whole blood test that could be performed and interpreted by
the bedside in addition to a clinically derived risk assessment score (RAS) to determine
whether a practical and cost-effective clinical model could be developed for the diagno-
sis and exclusion of DVT in symptomatic patients.
Methods: Two hundred consecutive patients who were referred to the vascular laborato-
ry with clinically suspected DVT underwent the following procedures: (1) clinical assess-
ment and stratification into low, moderate, or high risk for DVT on the basis of an RAS
related to history, symptoms, and physical examination findings; (2) rapid (5-minute)
whole blood D-dimer testing with a semi-qualitative agglutination technique on a fin-
gerprick blood sample; and (3) color flow duplex ultrasound scanning with standard cri-
teria for the diagnosis of proximal and calf DVT.
Results: Forty-six patients (23%) had acute DVT on duplex ultrasound scanning. Of
these cases, 28 (61%) had proximal DVT and 18 (39%) were confined to the calf. A total
of 88 patients were classified as low risk, 67 were classified as moderate, and 45 were
classified as high risk on the basis of the RAS method. Of the patients who were classi-
fied at low risk, 4.5% (4/88) had DVT, as compared with 17.9% (12/67) in the mod-
erate clinical risk group and 66.7% (30/45) in the high risk group. Isolated calf DVT
was found in 30% (9/30), 50% (6/12), and 75% (3/4) of the high, moderate, and low
risk groups, respectively. The sensitivity (8.7%, 26.1%, 65.2%), specificity (45.5%, 64.3%,
90.3%), positive predictive value (4.5%, 17.9%, 66.7%), and overall accuracy rate (37%,
55.5%, 84.5%) of the low, moderate, and high risk groups, respectively, in the diagnosis
of DVT increased significantly with increasing risk score stratification. The sensitivity,
specificity, positive and negative predictive value, and overall accuracy of the rapid D-
dimer test for all DVT were 91.3%, 81.9%, 60%, 96.9%, and 84%, respectively, with a
100% sensitivity and negative predictive value for proximal DVT. A combination of the
RAS and D-dimer identified a low risk group with a negative D-dimer as having less
than a 1% likelihood of DVT and a high risk group with positive D-dimer as having a
likelihood of more than 90%.
Conclusion: A combination of clinical assessment and rapid D-dimer testing provides an
effective means of excluding proximal DVT in symptomatic patients. The application of
a clinical diagnostic model on the basis of these parameters has the potential for saving
a large proportion of unnecessary duplex scans with the associated time and costs. 
(J Vasc Surg 1999;30:794-804.)
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The clinical diagnosis of symptomatic deep vein
thrombosis (DVT) remains inaccurate because of
the low sensitivity and specificity of the individual
symptoms, such as pain, swelling, and tenderness.1-5
More recently, attempts to improve the diagnostic
value of clinical assessment in the identification of
DVT in symptomatic patients have been made with
the introduction of a pretest probability that strati-
fies patients into high, moderate, and low risk
groups.6-8 The use of this method claims significant
improvements both in the diagnosis and in the
exclusion of DVT. However, the method cannot be
used alone in clinical decision making.
Most patients with symptoms that are suggestive
of DVT require objective testing to identify or
exclude the presence of thrombosis for the institu-
tion of appropriate early treatment, which tradition-
ally involves contrast venography. Today, duplex
scanning has essentially replaced venography in the
investigation of patients with suspected DVT, with
an ability to diagnose proximal thrombosis approach-
ing 100% in symptomatic patients.9-11 Venography,
although still considered the “gold standard,” is inva-
sive, expensive, and time consuming, has limited use
in patients with renal impairment, and can be associ-
ated with allergic reactions and the development of
DVT.12-14 Color flow duplex scanning, despite the
reported limitations in the assessment of the calf, par-
ticularly in asymptomatic patients who undergo
screening after surgery, permits the diagnosis of dis-
tal thrombosis with an accuracy rate of greater than
93% in an experienced, accredited vascular laborato-
ry.10 Unfortunately, the widespread acceptance and
the ease of its application have resulted in a constant-
ly increasing demand for scans in the investigation of
clinically suspected DVT, which is both time con-
suming and expensive in today’s environment of cost
containment. With vascular laboratories reporting
yields of positive scan results in less than 30% of the
scans,15,16 there exists a growing abuse of the duplex
scan facilities available and a steadily increasing work-
load is being placed on limited resources when its
application in noninvasive cardiovascular investiga-
tions is rapidly expanding.17
D-dimer levels have been widely reported as use-
ful predictors of the absence of both lower limb DVT
and pulmonary embolism18-29 because they are a
product of fibrin degradation and are considered to
indicate endogenous fibrinolysis in the presence of
intravascular thrombosis.30 Various methods have
been described in the literature. However, the most
widely adopted and reliable testing methods have
used enzyme-linked immunosorbent asssays (ELISA),
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which require complex laboratory equipment and
expertise and can be time consuming.20-22 A rapid
assay on the basis of a whole blood sample that can be
obtained and interpreted at the bedside holds the
potential to simplify the diagnosis of DVT by being
able to exclude patients without thrombosis, thereby
reducing the number of people being referred for
noninvasive testing unnecessarily. Such an assay could
only be applied to routine clinical practice if it reliably
excluded DVT in those patients who subsequently
required anticoagulation therapy to prevent the asso-
ciated thromboembolic complications.
The aim of this study was the determination of
the actual value of this test used individually and in
combination with clinically derived risk stratification
in the diagnostic workup of patients with suspected
lower limb venous thrombosis.
MATERIALS AND METHODS
During a 4-month period, 200 consecutive
patients (126 women [63%] and 74 men [37%];
mean age, 58 years; range, 18 to 91 years) who were
referred to the vascular laboratory with symptomatic
clinically suspected acute DVT were included in the
study population. Both inpatients (n = 118; 59%)
and outpatients (n = 82; 41%) underwent examina-
tion. Excluded from the study were patients with the
following characteristics: (1) previously diagnosed
DVT; (2) features of chronic DVT on duplex ultra-
sound scan results; (3) symptoms lasting in excess of
1 month; (4) therapeutic dose anticoagulation ther-
apy instituted for greater than 48 hours before
examination; or (5) clinically suspected or confirmed
pulmonary embolism with duplex ultrasound scan-
ning being performed to exclude thrombosis in the
absence of lower limb symptoms. Furthermore, any
patients at high risk who were referred to the vascu-
lar laboratory for screening without any specific leg
symptoms were not included in the study. The
patients who were undergoing prophylactic therapy
with unfractionated or low–molecular weight
heparin were not excluded from the study.
All the patients underwent clinical evaluation by a
single examiner and subsequent stratification of risk for
DVT by means of calculation of a risk assessment score
(RAS) on the basis of a simplified modification of a
previously published and validated model of pretest
probability (Table I).6-8 The patients in the low risk
group (RAS, <6) thus would have no more than one
primary risk factor, those in the high risk group (RAS,
>10) would have at least two or more primary factors,
and those in the moderate group would have various
combinations of both the primary and secondary
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points listed. Factors that have been reported previ-
ously to cause false positive D-dimer results, such as
recent major surgery, active infection, malignant dis-
ease, or trauma, were recorded. Each patient included
in the study was thereby stratified into a low, moder-
ate, or high risk group for the presence of DVT.
After informed consent was obtained, a finger-
prick whole blood sample was collected for a rapid
semi-quantitative D-dimer analysis by a second
examiner who was blinded to the result of the clini-
cal risk score. A single drop of blood was mixed with
a D-dimer antibody reagent (SimpliRED, Agen
Biomedical, Brisbane, Austrailia) that contained a
bispecific antibody that is formed with the conjuga-
tion of a high-affinity monoclonal antibody against
D-dimer to a red cell binding antibody. The sample
was mixed for as much as 5 minutes, with an elevat-
ed level at more than 200 ng/mL resulting in agglu-
tination of the blood (Fig 1). This may be visualized
as having either a weak or a strongly positive out-
come, but for this study all the tests that resulted in
any degree of agglutination were considered to have
positive results. All the tests with negative results
were then re-tested with a positive control sample
that was included in the kit to ensure that agglutina-
tion was possible in each patient sample.
All the patients underwent duplex ultrasound
scanning of the symptomatic limb or limbs by an
experienced vascular technologist who was blinded
to the results of the clinical assessment and D-
dimer test. The assessment of the proximal and calf
veins was performed according to techniques previ-
ously described10 with an HDI 3000 (Advanced
Technology Laboratories, Bothell, Wash) scanner
with a 4 to 7 MHz linear array probe. The criteria
for the identification of DVT included the presence
of a visible thrombus on B mode or filling defects
on color flow imaging, the incompressibility of the
vein, and the absence of phasic flow on respiration
or distal augmentation. Features, such as highly
echogenic thrombus, contracted and irregular vein
walls, and large, well-established venous collaterals
that suggested a chronic DVT, were also noted,
and these patients were excluded from further
study. Patients with a combination of both proxi-
mal and calf vein involvement were considered to
be in the proximal DVT group in the subsequent
analysis. Patients with an initially inconclusive scan
as the result of poor visualisation of the calf veins
were followed every 2 to 3 days with repeat duplex
scanning until a diagnosis was established. The D-
dimer test that was performed at the initial duplex
scan investigation then was compared with the
eventual duplex scan diagnosis. This laboratory has
previously reported a sensitivity of 100%, a speci-
ficity of 98.8%, and an overall accuracy rate of
99.4% in the identification of proximal DVT as
compared with venography in symptomatic patients
and a sensitivity of 87.5%, a specificity of 98.7%,
and an overall accuracy rate of 93.1% in the identi-
fication of calf vein thrombosis.10 The patients who
were found to have a positive diagnosis of either
proximal or isolated calf vein thrombosis were sub-
sequently managed by their referring physician on
the basis of their individual clinical requirements.
Fig 1. Whole blood D-dimer test results on basis of semi-
qualitative analysis of agglutination within 5 minutes. All
patients with weak or strong agglutination were consid-
ered to have positive D-dimer test results.
Table I. Evaluation of the risk assessment score
(RAS) for deep vein thrombosis (DVT) with med-
ical history and physical examination parameters
Primary factors (3 points each)
Active malignant disease (current or within previous 6 months)
Recently bedridden or limb immobilization or major surgery
within previous 4 weeks
Localized tenderness along the distribution of the deep veins
Thigh or calf swollen > 3 cm as compared with the asympto-
matic limb
Strong family history of DVT (‡ two first-degree relatives with
history of DVT) 
Secondary factors (1 point each)
History of recent lower limb trauma (<60 days) 
Unilateral pitting edema in the symptomatic limb
Dilated superficial veins (nonvaricose) on the symptomatic limb only
Hospitalization within the previous 6 months
Erythema of the symptomatic limb only
Risk stratification (maximum score = 20)
Low risk: RAS < 6 points
Moderate risk: RAS 6 to 10 points
High risk: RAS > 10 points
The examiner assesses each factor, and the score is calculated as
the sum of both primary and secondary factors in each patient.
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Statistical analysis. The efficacy of the clinical
risk stratification and the D-dimer testing was deter-
mined on the basis of the sensitivity, specificity, pos-
itive and negative predictive values, and overall accu-
racy rate. With regard to the performance of the
RAS in the identification of patients with DVT as
expressed in Table II, each risk category was assessed
individually with the identification of patients as true
positive (the presence of DVT within that risk
group) or true negative (the absence of DVT within
the other two risk groups) and false positive (the
absence of DVT within that risk group) or false neg-
ative (the presence of DVT within the other two risk
groups). The relative contribution of the clinical risk
scoring method and the D-dimer test used individu-
ally or in combination in the diagnosis of DVT is
expressed as likelihood, calculated on the basis of
Bayes’ theorem (Fig 3).31 The comparisons between
the risk groups were made with a 2· 3 c 2 test.
RESULTS
Of the consecutive patients who were referred to
the vascular laboratory, 32 were initially excluded
from subsequent analysis because of the criteria pre-
viously described. All the proximal vein segments
were adequately assessed at the initial examination.
However, 14 patients who were included in the study
had initially inconclusive scans of the calf veins as a
result of swelling and poor visualization and under-
went repeat scanning at 2-day to 3-day intervals. Of
the 200 patients included in the study, 46 (23%) were
identified as having DVT on duplex ultrasound scan-
ning. Of these patients, 28 (61%) had proximal vein
thrombosis (iliac, femoral, or popliteal) and 18 cases
(39%) were confined to the axial and muscular veins
of the calf. Isolated calf DVT was confirmed in two
of the 14 patients with initially inconclusive scans,
and the remaining 12 had no evidence of DVT on
follow-up examination. Both of the patients with
confirmed DVT had initially positive D-dimer test
results and were in the high risk group (RAS, >10).
Of the 118 inpatients studied, 30 were found to have
DVT (25.4%) as compared with 16 of the 82 outpa-
tients (19.5%), with no significant difference between
the groups (P = .53).
Fig 2 depicts the distribution of the patients into
low, moderate, and high clinical risk groups accord-
ing to the calculated RAS and the relationship to
Fig 2. Outcome of duplex ultrasound scanning and D-dimer testing in 200 patients with low,
moderate, and high risk according to risk assessment score. DD, D-dimer; +ve, positive; -ve,
negative.
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both the duplex and the D-dimer findings. A total of
88 patients (44%) were classified as low risk, 67
(33.5%) as moderate risk, and 45 (22.5%) as high
risk on the basis of clinical history and physical
examination. Only four patients (4.5%) who were
classified as low risk were identified with a DVT as
compared with 12 patients (17.9%) at moderate
clinical risk and 30 of 45 patients (66.7%) at high
risk. The proportion of isolated calf DVT was 30%
(9 of 30), 50% (6 of 12), and 75% (3 of 4) in the
high, moderate, and low risk groups, respectively.
The ability of the RAS to identify patients with
DVT is illustrated in Table II, with the sensitivity,
specificity, positive predictive value, and accuracy
rate all increasing significantly with a higher RAS
and subsequent stratification into a higher risk
group. Table III separates the various thrombotic
risk factors assessed in the calculation of the RAS.
Table II. Stratification into clinical risk groups (low, moderate, or high) on the basis of the risk assessment
score (RAS) and its efficacy in the diagnosis of deep vein thrombosis (DVT)
Low (<6; n = 88) Moderate (6 to 10; n = 67) High (>10; n = 45) P value
Sensitivity 4/46 (8.7%) 12/46 (26.1%) 30/46 (65.2%) <.01
Specificity 70/154 (45.5%) 99/154 (64.3%) 139/154 (90.3%) <.05
Positive predictive value 4/88 (4.5%) 12/67 (17.9%) 30/45 (66.7%) <.001
Negative predictive value 70/112 (62.5%) 99/133 (74.4%) 139/155 (89.7%) NS
Accuracy rate 74/200 (37%) 111/200 (55.5%) 169/200 (84.5%) <.01
Low RAS group: true positive (low RAS/DVT present; n = 4), true negative (moderate or high RAS/DVT absent; n = 70), false posi-
tive (low RAS/DVT absent; n = 84), false negative (moderate or high RAS/DVT present; n = 42).
Moderate RAS group: true positive (moderate RAS/DVT present; n = 12), true negative (low or high RAS/DVT absent; n = 99), false
positive (moderate RAS/DVT absent; n = 55), false negative (low or high RAS/DVT present; n = 34).
High RAS group: true positive (high RAS/DVT present; n = 30), true negative (low or moderate RAS/DVT absent; n = 139), false
positive (high RAS/DVT absent; n = 15), false negative (low or moderate RAS/DVT present; n = 16).
Risk assessment score: maximum = 20.
Fig 3. Intermediate pre-test and post-test likelihoods (Lo to L2) of clinical risk stratification
and D-dimer assay results and number of symptomatic patients with DVT identified with
duplex ultrasound scanning. +ve, Positive; -ve, negative.
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Although there was no significant difference in the
sensitivities or negative predictive values of the dif-
ferent risk factors on an individual basis, the number
of false positives (n = 8) in the 28 patients with an
associated malignant disease was significantly greater
than the number of false positives in the patients
without a malignant disease (P = .03). The ability of
D-dimer testing alone to identify patients with prox-
imal and calf DVT is summarized in Table IV.
Although the sensitivity, specificity, positive and neg-
ative predictive values, and overall accuracy rate of
the test is higher for proximal DVT than for isolated
calf DVT, the difference fails to reach statistical sig-
nificance. The test provides 100% sensitivity and
negative predictive values in the diagnosis of proxi-
mal DVT, irrespective of the application of the clin-
ical scoring system. There were four patients with
small localized isolated calf vein thrombi that had
negative D-dimer assay results, three of which
occurred in patients classified at moderate risk and
one classified at low risk. None of these four patients
underwent anticoagulation therapy, and, on follow-
up scanning every 3 days, there was no evidence of
propagation into the proximal veins by 2 weeks.
Furthermore, the clinical course of these patients
was not complicated by either progression of local
symptoms or clinically evident pulmonary emboli.
There was no difference in the incidence of DVT
between the inpatient and outpatient groups for the
three risk categories. In addition, the performance of
the D-dimer test (sensitivity, specificity, positive and
negative predictive values) was not significantly dif-
ferent between these two patient groups (p > .05).
All the patients with falsely positive D-dimer test
results (n = 28) had either an alternative diagnosis
that accounted for the lower limb symptoms (celluli-
tis, n = 5; ruptured Baker’s cyst, n = 2; superficial
thrombophlebitis, n = 3; hematoma, n = 2) or had
either undergone recent surgery (n = 10) or had co-
existing acute medical conditions (n =6). Four of the
12 patients (33%) with initially inconclusive scan
results who subsequently had negative follow-up scan
results had false positive D-dimer test results. There
were 71 inpatients (60%) who underwent prophylac-
tic therapy with either unfractionated or low–molec-
ular weight heparin, 12 of whom had DVT con-
firmed on duplex scanning. There was no significant
difference between the number of false positive D-
dimer test results in this group as compared with
those results in the inpatient and outpatient groups
without any anticoagulation therapy (12 vs 16; P =
NS), and none of the four patients with a false nega-
tive test result were undergoing heparin therapy.
The addition of the rapid D-dimer test to the risk
stratification of the patients with respect to DVT
enhances the value of the clinical criteria alone in the
Table III. Thrombotic risk factors, incidence of deep vein thrombosis, and performance of D-dimer test
in patients with known risk
Surgery Immobility Trauma Family history Malignant disease 
(n = 48) (n = 62) (n = 35) (n = 18) (n = 28)
Incidence DVT 10/48 (20.8%) 9/62 (14.5%) 14/35 (40%) 3/18 (16.7%) 8/28 (28.6%)
Sensitivity DD 100% 90% 93.3% 100% 100%
Specificity DD 73.7% 88.5% 75% 93.3% 60%
PPV DD 50% 60% 73.7% 75% 50%
NPV DD 100% 97.9% 93.8% 100% 100%
DVT, Deep vein thrombosis; DD, D-dimer; PPV, positive predictive value; NPV, negative predictive value.
Table IV. Sensitivity, specificity, predictive value, and overall accuracy rate of rapid D-dimer testing in the
identification of patients with either proximal (iliac, femoral, popliteal) or isolated calf (tibial, peroneal,
muscular) vein thrombosis
Deep vein thrombosis
Proximal (n = 28) Isolated calf (n = 18) P value All (n = 46)
Sensitivity 100% 81.9% NS 91.3%
Specificity 75.6% 69.2% NS 81.9%
Positive predictive value 40% 20% NS 60%
Negative predictive value 100% 96.9% NS 96.9%
Accuracy rate 79% 70% NS 84%
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identification of patients with DVT and the exclusion
of those without DVT (Fig 3). The improvement is
seen in all the stratification groups. However, it is
most evident in the low and moderate risk groups in
which the likelihood of positive duplex scan results in
the presence of a positive D-dimer more than triples
that of clinical assessment alone. Furthermore, the
ability to exclude the presence of DVT (specificity
and negative predictive value) is markedly enhanced.
DISCUSSION
This study shows that the clinically derived RAS
method enables the clinician to identify the subgroup
of patients who are indeed at high risk for DVT. The
modification of a previously validated pretest proba-
bility6-8 on the basis of a simple scoring system relat-
ed to both major and minor factors in the medical
history and clinical examination allowed stratification
into three risk groups. The patients in the high risk
group were associated with a 66% DVT likelihood as
compared with an 18% and 5% likelihood in the
moderate and low risk groups, respectively. Although
it is true that individual symptoms and signs, such as
pain, swelling, and limb tenderness, are notoriously
inaccurate predictors of DVT, their cumulative use in
conjunction with other parameters derived from the
medical history provide the additional information to
discriminate between those patients at high risk and
those patients who are significantly less likely to have
a thrombosis. Despite the potential benefits that are
offered by this stratification method, a significant
number (16 of 46; 35%) of the DVTs were found in
patients who were allotted into the low and moder-
ate risk groups. With the consideration of patients in
the moderate and high risk groups together, the scor-
ing system enables more than 91% (42 of 46) of
those patients with DVT to be identified by means of
clinical assessment alone. Of the remaining four
patients with DVT who were allotted to the low risk
group, three had isolated calf vein thrombosis, with
only one patient in the 28 with proximal DVT being
missed on clinical grounds.
The potential role of D-dimer assays in the diag-
nosis of patients with suspected venous thromboem-
bolism has been studied previously.18-29 Of these
studies, the latex methods require plasma preparation
and yield insufficient sensitivity and the ELISA-based
techniques, which are considered to have the highest
sensitivity and negative predictive values, require lab-
oratory expertise, with the results taking from 30
minutes to several hours to acquire. Furthermore, all
of these methods are characterized by limitations in
their specificity caused by other conditions that may
activate the coagulation and fibrinolytic cascades, pro-
ducing a false positive result.19,21,32 Our data show
that rapid D-dimer testing in patients with clinically
suspected DVT, if those patients with previous
thrombosis or undergoing prolonged heparin therapy
are excluded, provides a 100% sensitivity in the diag-
nosis of proximal thrombosis and has an equal ability
to exclude it in the presence of negative test results.
Accordingly, in the presence of negative test results, a
patient could safely avoid further investigations for
the diagnosis of proximal thrombosis, despite the fact
that a proportion of patients will proceed to undergo
duplex scanning, which can be used to identify other
pathologic processes, such as ruptured Baker’s cysts,
hematomas, or superficial thrombophlebitis.
The method is much less sensitive in the diagno-
sis of isolated calf vein thrombosis, with only 14 of
the 18 patients with calf DVT on the basis of duplex
scanning having positive D-dimer test results. In the
presence of a negative D-dimer, the possibility of
distal thrombosis cannot be entirely excluded. These
patients with false negative D-dimer results did not
proceed to undergo venography to confirm the true
presence of thrombosis because this was not a part
of the protocol, and thus the possibility that these
findings represent falsely positive duplex scan results
cannot be excluded and the sensitivity in calf vein
thrombosis could actually be higher. Conversely,
because no patient underwent standard reference
ELISA testing to confirm the quantitative D-dimer
level, it is feasible that the rapid agglutination test
was a falsely low reading in these four patients.
Previous studies that compared the rapid agglutina-
tion testing kits with the ELISA techniques have
shown comparable sensitivities and negative predic-
tive values.22,23,33 The significant proportion of false
positive results limits the specificity and positive pre-
dictive value of this method but not its ability to
exclude proximal thrombosis and, to a lesser extent,
isolated DVT, both of which have clinical signifi-
cance. Most patients with positive test results with-
out duplex scan evidence of DVT had undergone
recent surgery or had an alternative diagnosis for
their lower limb symptoms, such as cellulitis or a
ruptured Baker’s cyst, and, in symptomatic patients
in whom other diagnoses are suspected, the applica-
tion of such a screening test is obviously limited.
The use of the rapid D-dimer test combined with
clinical risk stratification enables the exclusion of a
DVT in the low risk group when the D-dimer test
results are negative, with the likelihood of DVT in this
instance being less than 1%. In patients at moderate
DVT risk, the likelihood of thrombosis in the presence
of a negative D-dimer increases to only 2%. On the
other hand, in the presence of positive D-dimer test
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results, more than 90% of patients at high risk are
found to have DVT. Furthermore, in this series, there
were no patients stratified into the high risk group
with negative D-dimer test results who were found to
have DVT. All the D-dimer tests that resulted in
missed thromboses involved small isolated calf veins,
which are known to propagate in 8% to 23% of
patients, many of which extend into the popliteal vein
and may be associated with either pulmonary or post-
thrombotic complications.34-37 Although the D-dimer
test may overlook a small number of isolated calf vein
thromboses, not all institutions treat calf DVT with
full anticoagulation therapy, particularly in mobile
patients who have small thrombi distal to the popliteal
vein. Such protocols, however, do require follow-up
scanning to exclude propagation, and, should it occur,
anticoagulation therapy is invariably indicated.
We propose a new strategy in the diagnostic
workup of patients with clinically suspected DVT as
illustrated in Fig 4. All the patients after clinical exam-
ination are stratified into high, moderate, and low risk
groups according to the suggested RAS method. With
this conservative approach, all the patients who are
allocated to moderate and high risk groups undergo
lower limb venous duplex scanning, with those with
positive test results undergoing treatment on the basis
of their individual clinical needs. Those patients with
isolated small thromboses who are mobile can often
undergo treatment without full anticoagulation thera-
py provided repeat scanning can be performed to
exclude any proximal propagation. The patients who
are at low clinical risk for DVT will undergo a rapid
bedside D-dimer test, with only those with positive
results proceeding to undergo duplex scanning. All the
patients at low risk who have negative duplex scan
results with imaging of the proximal and calf veins do
not require further investigation for the exclusion of
DVT. It can be argued that those patients at moderate
to high clinical risk should undergo repeat duplex
scanning at 1 week to exclude the presence of DVT as
indicated in Fig 4. This rationale has been proposed by
authors, with clinical criteria combined with compres-
sion ultrasound scanning8 or with compression B-
mode ultrasound scanning of the proximal veins
alone.38,39 These repeat studies are performed to
exclude a propagated calf thrombosis that was not
assessed at the initial scan, and they have shown a
thromboembolic complication rate of less than 0.7% in
the follow-up period. The safety of the performance of
only a single technically adequate color flow duplex
scan of all vein segments to exclude subsequent DVT,
although now widely practiced, has yet to be estab-
lished prospectively. Finally, the patients at low clinical
risk with negative D-dimer test results who have a less
than 1% likelihood of DVT should be spared further
diagnostic evaluation unless there is deterioration in
their lower limb symptoms, at which time they should
be referred for clinical re-evaluation. If a missed calf
Fig 4. Proposed diagnostic strategy in exclusion of suspected deep vein thrombosis in sympto-
matic patients with combination of clinical risk assessment and rapid whole blood D-dimer test.
+ve, Positive; -ve, negative.
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vein thrombosis has propagated into the more proxi-
mal veins, accounting for the new symptoms, it is
potentially feasible according to our data (100% sensi-
tivity for proximal thrombosis) that a repeat D-dimer
at this stage can be used to identify this complication.
The ability of a rapid D-dimer to assess the progress
and to identify regression or propagation of DVT both
proximally and distally has not been addressed in this
study and requires further evaluation. Furthermore,
the finding of the D-dimer being more sensitive for
proximal DVT in comparison with calf DVT, particu-
larly small isolated thrombi, may be the result of the
higher degree of endogenous fibrinolysis that has
occurred when there is a larger thrombus load.
However, this has also not been specifically studied.
Our data indicate that the use of the rapid D-dimer
test combined with clinical risk stratification identifies
patients with clinically suspected DVT in whom prox-
imal lower limb thrombosis can be reliably excluded,
providing the potential of significant time and cost sav-
ings. A duplex scan is estimated to cost $150 per pro-
cedure and takes approximately 20 minutes to com-
plete a full examination of each limb, and the D-dimer
kit costs approximately $7 per test and only takes 5
minutes to perform and interpret the results. With the
information derived from the current study, 88 of the
200 patients were found to have a low clinical risk
score and would proceed to D-dimer testing according
to the described protocol. Negative D-dimer results
occurred in 77 of these patients, and thus, only 11 in
this risk category with positive results together with all
patients in the moderate and high risk groups would
have proceeded to undergo duplex scanning. There
would be an initial cost saving of approximately $4770
per 100 patients undergoing investigation, together
with 13 hours of saved duplex scanning time. In the
patient cohort studied, those with malignant disease as
a risk factor were more likely to have a false positive D-
dimer result as compared with those without malig-
nant disease. Thus, the clinical applicability of the test
in this patient subgroup would be less cost effective
than in patients with other risk factors, such as immo-
bility or recent surgery, despite the fact that a negative
test result is still as likely to be associated with the
absence of DVT in patients with all types of throm-
botic risk. In a vascular laboratory that examined more
than 1000 patients with clinically suspected acute DVT
annually, despite the potential limitations of this proto-
col in patients with long-standing symptoms, in those
patients with previous thromboembolic events, and in
those patients undergoing prolonged heparin therapy
who were excluded in this study, significant savings
could be made with respect to valuable duplex scan
equipment and operator time, which could then be
allocated to other noninvasive vascular investigations.
The attractive options provided by the SimpliRED
D-dimer assay include the ability to perform the test
on a single drop of whole blood without complex lab-
oratory equipment or preparation of a plasma sample
and the ability to give a result within 5 minutes. This
test has a high reported interobserver agreement,
between-assay agreement, and reproducibility in
excess of 95%40 when the subjectivity of the test result
is reduced by limiting the degree of agglutination to
either a positive or negative reading. When compared
with the “gold standard” of venography, the test has
been shown to have a sensitivity for identifying prox-
imal DVT of 93% to 100% and a negative predictive
value of 98% to 100%.19,23 Furthermore, the perfor-
mance of the bedside test against the more tradition-
al ELISA test with a cut-off value of 500 ng/mL 
has been validated, with a negative predictive value of
95% for the rapid agglutination test as compared with
96% for the ELISA.33 These factors could make it
suitable for widespread use not only in the hospital
but also in an outpatient and emergency department
setting where patients with negative results could be
spared further investigation or even after hours hospi-
tal admission with anticoagulation therapy while
awaiting diagnostic evaluation.
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DISCUSSION
Dr Jon S. Matsumura (Chicago, Ill). I would like to
thank the program committee for the privilege of dis-
cussing this paper and the authors for providing an
advance version of the paper.
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There is an important need to develop a rapid, inex-
pensive, and sensitive test that will help spare our skilled
colleagues in the blood flow laboratory from the inappro-
priate use of this resource, and I think that this study helps
us to address this need. I have several questions, however.
With any subjective diagnostic test, we must be sure
that observer bias has been excluded, and I noticed in your
presentation that you stated that the rapid D-dimer was
done independently. Would you elaborate on exactly how
we can be assured that was done independent of the clin-
ical score and the duplex scan results, especially given that
if the patient had a chronic DVT on the duplex scan they
were subsequently excluded from the study?
Secondly, we have to understand whether these results
are applicable to those of us who practice at other hospitals
and what population of our blood flow laboratory requests
could benefit from this. For that perspective, what percent-
age of your patients in your blood flow laboratory seen dur-
ing these 4 months for duplex scan examination were
excluded on the basis of the four criteria that you gave?
Along those same lines, your paper cited a duplex scan accu-
racy rate of 90% to 100% and this may be different from
other blood flow laboratories with less accuracy. In the
patients with moderate and high clinical risk who undergo a
positive rapid D-dimer and then go on for a negative duplex
scan examination, do you really stop the workup at that
point? I think, in some hospitals, we would either empirical-
ly treat those patients, get a venogram, or do serial noninva-
sive testing. This was the case in 10% of your 200 patients,
and do you have any long-term data on those patients to see
whether there is any subsequent diagnosis?
Finally, I am interested in the false-positive rapid D-
dimer tests and curious about those four patients who you
have who had the false-negative D-dimer but a duplex
scan–detected calf DVT. Did you do a standard quantitative
D-dimer in those patients? Do we know if the false-negative
was because of the rapid whole blood assay, or was it nega-
tive because there is actually a low D-dimer level in the
patient? Could those patients actually have had a false-posi-
tive ultrasound scan test?
Dr Andrew F Lennox. Thanks Dr Matsumura. I will
try and answer most of those questions.
The answer to the first one, about the testing tech-
niques, is that the patients arrived to the vascular laboratory
and had a duplex scanning procedure performed. All the
patients obviously being referred at this stage went on to
have the test performed regardless of whether they fit into
the exclusion or inclusion criteria. If the patient was diag-
nosed with a recurrent DVT or a chronic DVT, then they
were spared. They were not included in the study and did
not go on to have the D-dimer testing or the risk score strat-
ification. So, all the patients underwent the testing, but not
all were not included for further analysis. We specifically lim-
ited those subgroups to avoid a number of false-negative
results because the actual use of this test is being proposed
for acute symptomatic patients. The patients then went on
and had an independent examiner blinded to the result of
the duplex scan do the D-dimer test. We encouraged the
patients not to discuss their duplex scan findings with the
person doing the test.
As far as the accuracy of our duplex scanning is con-
cerned, we are aware of a varying efficacy of duplex scan,
particularly in the calf veins. We have reported from our lab-
oratory a few years ago in the European Journal of Vascular
Surgery the accuracy in picking up calf vein thrombosis as
compared with venography in 100 patients, which give
these figures. These are some years old, and, since then,
both technologists and the duplex scan equipment have
advanced to the point to where we are confident that these
figures are correct.
With regard to the number of false positive results that
we saw, there were 14% of false positives. We accept the lim-
itations of this test in finding patients with false positives. All
of these patients with these false positive results did have
other reasons to have a false positive, either being postsurgi-
cal or showing other pathology. I think the use or the appli-
cability of this test is not limited particularly by the false pos-
itive results because these patients will go on to have further
investigation. Some other centers have gone on to use
venography in those patients with a false positive result who
then have a subsequent negative duplex ultrasound scan, and
some continue to have follow-up examinations with a
thromboembolic complication rate of less than 0.5%. So, we
believe that we would be missing a small number of patients
if we relied purely on the duplex ultrasound scan results.
Dr D. Eugene Strandness, Jr (Seattle, Wash). We
share your anxiety about the necessity of getting a better
yield, if you will, on duplex scans. In our place, it is about
12%. The problem I have with your study is that I do not
know an American physician who would use a clinical
grading scale like you have emphasized. In fact, we cannot
even get rid of Homans’ sign. I wonder if you have any
solution to that.
Dr Lennox. It may be a bit easier in the hospital setting.
If you were to use this sort of system widely in your hospital,
you would have to have acceptance from the physicians who
are referring the patients to you. Particularly in the patients
with a lot of clinical signs and a strong history suggestive of
DVT, it is going to be difficult to say to those referring physi-
cians that your patient does not need a duplex scan because it
will not only pick up thrombosis. But you will also find, in
some cases, ruptured Baker cysts, and you will find hematoma
and popliteal artery aneurysms in a small percentage, and the
duplex scan has the advantage of giving you a diagnosis even
if it is not DVT in some patients. That is why we have pro-
posed a more conservative algorithm of investigation in
which only those patients with minimal clinical signs and his-
tory and therefore a low likelihood of DVT would be spared
further investigation in the presence of a negative D-dimer
test. Other people would suggest that all patients undergo D-
dimer testing and that only those patients with positive exam-
ination results go on to investigation.
